Proactive Investors - Run By Investors For Investors

Imugene targets cash injection for immuno-oncology clinical testing

The halt will remain in place until Thursday 23rd November 2017.
Imugene targets cash injection for immuno-oncology clinical testing
The company's shares are in pre-open

Imugene Ltd (ASX:IMU) has commenced clinical testing a therapeutic anti-cancer vaccine called HER-Vaxx (IMU131), in HER2+ gastric cancer patients.

HER-Vaxx is a next generation HER2 cancer therapy using B cell peptides, which harness the body’s ability to develop antibodies against the disease.

HER-Vaxx works by targeting the same receptor as Herceptin and Perjeta, two leading antibody drugs marketed by Roche, with annual sales of US$8.2 billion.

To progress the next steps, Imugene is heading to market with a capital raising, and the ASX has granted the company a trading halt to prepare.

The halt will remain in place until the opening of trade on Thursday 23rd November 2017, or earlier if an announcement is made to the market.

View full IMU profile View Profile

Imugene Ltd Timeline

Related Articles

Woman touching face
May 01 2019
The SkinBiotix platform uses lysates (extracts) of probiotic bacteria to help increase the integrity of the skin as a barrier against toxins and other harmful elements while also improving its healing rate and infection resistance
antibodies
May 02 2019
Avacta is using Affimers to develop its own cancer therapy, but it also licenses the technology to other companies, including major pharma group ModernaTX and LG Chem Life Sciences
Scientists in a lab
January 31 2019
CEO Gary Phillips says Pharmaxis’ healthy cash balance gives it time to choose between in-house and partnering options.

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use